TRAVERE THERAPEUTICS, INC. Amortization of Debt Issuance Costs
TRAVERE THERAPEUTICS, INC. (TVTX) reported Amortization of Debt Issuance Costs of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2017-03-01
- TRAVERE THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2014-12-31 was -$280.00.
- TRAVERE THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2014-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2016 was $0.00.
- TRAVERE THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- TRAVERE THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2014 was $4.71M.
- TRAVERE THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2013 was $0.00.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month | Amortization of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 | ||||
| 2014-12-31 | -$280.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$280.00 derived: sum of 2 quarters · filed 2017-03-01 | $4.71M 10-K · filed 2017-03-01 | $4.71M 10-K · filed 2015-03-11 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $4.71M 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $4.71M 10-Q · filed 2014-08-14 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |